首页> 外国专利> Non-Activated Platelet Transfusion Methods for Enhancement of Patient Treatment Outcomes

Non-Activated Platelet Transfusion Methods for Enhancement of Patient Treatment Outcomes

机译:非活化血小板输注方法可增强患者治疗效果

摘要

To reduce the complexity and risk associated with activated platelet transfusions, thrombocytopenic patients are transfused with exclusively non-activated platelets. A preferred embodiment is through routine screening of platelet units in the hospital blood bank using dynamic light scattering and selective allocation of platelets, with non-activated platelets being exclusively transfused to thrombocytopenic patients, especially patients with cancers such as hematologic malignancies. Activated platelets typically contain activated factors of the innate immune system called complement, transforming growth factor beta (TGFβ), interleukin 6 (IL-6), CD40 ligand (CD40L) and C-reactive protein (CRP) for example. Some of these activated factors have already been shown to correlate with microparticles and others are expected to correlate: the higher the platelet activation the more microparticles and the higher the concentration of these factors. By transfusing only non-activated platelets, therapeutic outcomes are enhanced.
机译:为了降低与活化血小板输注相关的复杂性和风险,将血小板减少症患者仅接受非活化血小板输注。一个优选的实施方案是通过使用动态光散射和血小板的选择性分配来常规筛选医院血库中的血小板单位,其中未活化的血小板仅输注到血小板减少症患者,特别是患有诸如血液系统恶性肿瘤的癌症的患者。活化的血小板通常包含先天性免疫系统的活化因子,称为补体,转化生长因子β(TGFβ),白介素6(IL-6),CD40配体(CD40L)和C反应蛋白(CRP)。这些活化因子中的一些已经显示出与微粒相关,而其他一些则预期相关:血小板活化越高,微粒越多,这些因子的浓度越高。通过仅输注未激活的血小板,可提高治疗效果。

著录项

  • 公开/公告号US2019204202A1

    专利类型

  • 公开/公告日2019-07-04

    原文格式PDF

  • 申请/专利权人 LIGHTINTEGRA TECHNOLOGY INC.;

    申请/专利号US201816209387

  • 发明设计人 ELISABETH MAURER;DANIEL MILLAR;

    申请日2018-12-04

  • 分类号G01N15/06;A61K35/19;

  • 国家 US

  • 入库时间 2022-08-21 12:06:31

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号